Dermatology · Philadelphia, PA
NPI
1821280298
Since 2007
Specialty
Dermatology
Code 207N00000X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
3400 Civic Center Blvd, 1-330s Perelman Center
Philadelphia, PA, 19104
Phone (215) 662-2737
Groups this clinician bills Medicare through
Medicare paid, 2024
$4,661
114 services
Medicare patients, 2024
40
Average age 71
Drug cost, 2024
$2.4M
431 prescriptions
Company payments, 2025
$6,693
From 3 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Junko Takeshita was code 99213 (office e&m - established), 53 times for 37 patients. In total Junko Takeshita billed 114 services in 9 codes, and Medicare paid $4,661.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2012-08-20.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Facility | 53 | 37 | $49.31 | $2,614 |
| 17110 Destruction Skin Lesion | Facility | 12 | 11 | $51.91 | $623 |
By year: 2022 $4,744 for 115 services; 2023 $3,249 for 80 services; 2024 $4,661 for 114 services.
Medicare prescription drug claims, 2024
In 2024, the drug Junko Takeshita prescribed most often to Medicare patients was Tremfya (Guselkumab), with 64 prescriptions and refills. In total Junko Takeshita wrote 431 Medicare prescriptions that cost $2.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Tremfya Guselkumab | 64 | 94 | Under 11 | $838K |
| Otezla Apremilast | 43 | 49 | Under 11 | $218K |
| Clobetasol Propionate Generic | 42 | 46 | 19 | $2,716 |
| Triamcinolone Acetonide Generic | 23 | 33 | 16 | $385 |
| Taltz Autoinjector Ixekizumab | 23 | 23 | Under 11 | $167K |
| Taltz Syringe Ixekizumab | 23 | 23 | Under 11 | $183K |
| Hydrocortisone Generic | 19 | 21 | Under 11 | $63.36 |
| Skyrizi Risankizumab-Rzaa | 16 | 45 | Under 11 | $317K |
| Calcipotriene Generic | 16 | 20 | Under 11 | $2,949 |
| Skyrizi Pen Risankizumab-Rzaa | 15 | 41 | Under 11 | $303K |
| Fluocinolone Acetonide Fluocinolone/Shower Cap | 12 | 12 | Under 11 | $664 |
| Enbrel Etanercept | 12 | 12 | Under 11 | $85K |
| Enbrel Sureclick Etanercept | 12 | 13 | Under 11 | $96K |
| Cosentyx Sensoready (2 Pens) Secukinumab | 11 | 12 | Under 11 | $87K |
| Methotrexate Methotrexate Sodium | 11 | 11 | Under 11 | $41.55 |
Brand drugs: 263 claims; generic drugs: 168 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Junko Takeshita $6,693 ($6,693 in general payments such as food, travel and fees) from 3 companies. The largest payer was E.R. Squibb & Sons, L.L.C. with $5,145.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.